Cyclothymia

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
Thursday, May 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.

Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

Retrieved on: 
Tuesday, April 16, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Cyclothymia, Major depressive disorder, Diabetes, Depression, Literature, Obesity, DNA, DSM-IV codes, Patient, MADRS, Gene expression, DNA repair, SIRT6, Biomarker, Ageing, Clinical trial, Arrivo, MDD, Pharmaceutical industry

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

Key Points: 
  • Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
  • This registration-quality Phase 2b study will enroll 450 subjects with MDD and evaluate the effectiveness of SP-624, a SIRT6 activator and novel mechanism of action, compared to placebo in treating adults with Major Depressive Disorder.
  • The SP-624-202 study will assess the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) as its primary endpoint.
  • The MADRS is a 10-item depression rating scale commonly used to assess the severity of depression in clinical trials.

PsyRx Advances Clinical Trial Exploration with Successful Completion of Toxicological Safety Study in Rats

Retrieved on: 
Monday, March 25, 2024
Pharmacy, MDD, SSRI, Human, Patient, Cyclothymia, Hope, Research, Animal, Major depressive disorder, TEL, Clinical trial, Ibogaine, Safety, Pharmaceutical industry

TEL AVIV, Israel, March 25, 2024 /PRNewswire/ -- PsyRx, a leading innovator in pharmaceutical research, is pleased to announce the successful conclusion of the live phase of a toxicological safety study involving the combined treatment of SSRI plus ibogaine.

Key Points: 
  • TEL AVIV, Israel, March 25, 2024 /PRNewswire/ -- PsyRx, a leading innovator in pharmaceutical research, is pleased to announce the successful conclusion of the live phase of a toxicological safety study involving the combined treatment of SSRI plus ibogaine.
  • This groundbreaking study is a pivotal step in the company's ongoing evaluations for conducting a clinical trial in humans, specifically focusing on patients suffering from Major Depressive Disorders (MDD).
  • During the 14 consecutive treatment days, the study examined the safety of administering the combined treatment at three different dose levels—low, medium, and high.
  • The successful completion of this toxicological safety study marks a significant achievement in the pursuit of improving the lives of individuals affected by MDD.

Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting

Retrieved on: 
Tuesday, December 5, 2023
Neuropsychiatry, Treatment, DSM-IV codes, IND, Grammatical mood, Depression, Prevalence, Literature, Mouse, Human, DSM-5, Cyclothymia, MADRS, Anxiety, Prefrontal cortex, Hallucination, Annual general meeting, Clinical Global Impression, CNS, Social, Poster, American College, Restless, Central nervous system, MDD, Patient, Therapy, Lumateperone, Pharmaceutical industry

NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting.

Key Points: 
  • Company presents preclinical data on ITI-1549, our lead product candidate in our non-hallucinogenic psychedelics program in mood disorders and other psychiatric disorders.
  • NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting.
  • Inner tension is an item within the MADRS which is often used as a surrogate marker for anxiety.
  • The data presented in this poster represent further analyses from Study 403.

Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting of the American College of Neuropsychopharmacology

Retrieved on: 
Thursday, December 7, 2023
Mental Health, Technology, Neurology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Brain, Schizophrenia, Depression, Electroencephalography, Safety, Deficit spending, Dean (education), Grammatical mood, PD, Clinical trial, Data, Patient, American College, American College of Neuropsychopharmacology, Cross, DSM-IV codes, MADRS, Cognition, Cyclothymia, MD, Harvard Medical School, Translational research, Massachusetts General Hospital, ERP, Neuroscience, EEG, Mental health, Biomarker, MDD, Medical imaging, Phosphorus, Medical device, Pharmaceutical industry, Alto

Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.

Key Points: 
  • Alto Neuroscience, Inc. today announced details from three presentations on clinical development programs presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP) that took place in Tampa, Florida, from December 3-6, 2023.
  • Alto’s data demonstrate advancements in biomarker identification for precision psychiatry and the potential to improve upon the trial-and-error approach to mental health treatment.
  • The company’s AI-enabled Precision Psychiatry Platform™ is designed to predict clinical response and match each patient to the right Alto product candidate through identifying, and prospectively replicating, brain biomarkers by analyzing data generated from EEG activity, neurocognitive task performance, wearable devices, and other measures.
  • Additionally, Alto is advancing ALTO-101 into a Phase 2 proof of concept study in patients with cognitive impairment associated with schizophrenia, with topline data expected in 2025.

NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event

Retrieved on: 
Monday, December 11, 2023
Therapy, Dark Enlightenment, Urine, Pain, GMP, HOPE, Beacon Grand Hotel, Comment, IND, DCS, Patient, Alvogen, FDA, DSM-IV codes, Cyclothymia, Conference, NIH, Low back pain, HEAL, Powell Street, Chronic pain, Ketamine, Bipolar, Pharmaceutical industry

RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Key Points: 
  • RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.
  • NRx currently has four (4) near-term shots on goal with meaningful commercial and/or monetization opportunities:
    NRX-100 – Intravenous Ketamine.
  • NRx will be hosting 1x1 meetings at the Beacon Grand Hotel (450 Powell Street, a block away from the JP Morgan Conference at Union Square).
  • To schedule a meeting, please register at LifeSci Partners Corporate Access Event 2024 and request a meeting with management.

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Retrieved on: 
Monday, October 23, 2023
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Lithium, Post-traumatic stress disorder, MTD, Trial of the century, IND, MDD, Food, Clinical research associate, Depression, Bipolar disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cyclothymia, BD, Index, Brain, NDA, Safety, IIA, Patient, TDM, Communication, Lithium toxicity, Pharmaceutical industry, Medical device

Although the ideal role for lithium augmentation has yet to be established, there is evidence to support the clinical practice of adding lithium to conventional antidepressants in pursuit of MDD remission.

Key Points: 
  • Although the ideal role for lithium augmentation has yet to be established, there is evidence to support the clinical practice of adding lithium to conventional antidepressants in pursuit of MDD remission.
  • AL001 is a novel lithium-delivery system that has the potential to provide benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium.
  • “This IND submission represents the next key milestone for Alzamend as we further advance our proprietary pipeline,” said Stephan Jackman, Chief Executive Officer of Alzamend.
  • We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression

Retrieved on: 
Monday, October 16, 2023
TMS, Brainsway, Hope, HDRS, Medicine, MD, DSM-IV codes, Patient, FDA, Psychiatry Research, Maintenance, Deep, Safety, Depression, Transcranial magnetic stimulation, TASE, Cyclothymia, MADRS, MDD, Research, Quality of life, Pharmaceutical industry

The compelling results were published in the peer-reviewed journal, Psychiatry Research, in an article titled, " Real-World Efficacy and Safety of Various Accelerated Deep TMS Protocols for Major Depression ."

Key Points: 
  • The compelling results were published in the peer-reviewed journal, Psychiatry Research, in an article titled, " Real-World Efficacy and Safety of Various Accelerated Deep TMS Protocols for Major Depression ."
  • Deep TMS utilizes specially designed H–Coils to stimulate deep and broad cortical regions associated with depression.
  • Data collected using this approach to treat depression was compiled from clinical sites and analyzed in this study.
  • We intend to further investigate the potential efficacy of accelerated Deep TMS in the treatment of MDD, and look forward to sharing those results.”

Neurolief Appoints Neurotechnology Business Leader Steve Beller as Chief Commercial Officer

Retrieved on: 
Wednesday, October 11, 2023
Innovation system, TMS, CCO, Spinal cord, St. Jude Medical, Brain, Strategic planning, Transcranial magnetic stimulation, Electricity, Myenteric plexus, Depression, History, Chronic pain, Cyclothymia, Patient, Management, Nursing, Pharmaceutical industry

TAMPA, Fla., Oct. 11, 2023 /PRNewswire/ -- Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).

Key Points: 
  • TAMPA, Fla., Oct. 11, 2023 /PRNewswire/ -- Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).
  • Steve has a demonstrated history of success in building diverse and high-performing commercial organizations in the neuromodulation and mental health markets.
  • "I am delighted to welcome Steve to the Neurolief team," said Scott Drees, CEO of Neurolief.
  • "I am glad to welcome Steve to Neurolief team," said Amit Dar, Founder and Chief Technology Officer of Neurolief.

The Center for Neuropsychiatry and Brain Stimulation (CNBS) Opens in Cary, North Carolina: Pioneering a Revolutionary Approach to Mental Health Treatment

Retrieved on: 
Saturday, September 30, 2023
Anxiety, Sleeping disorders following traumatic brain injury, TMS, CNBS, Doctor of Philosophy, Depression, Suite, Cyclothymia, Johns Hopkins University, MD, Patient, Brain, Transcranial magnetic stimulation, Knowledge, FDA, Mental health, Neurology, Behavioral neurology, Medical device, Nursing, Neuropsychiatry

CARY, N.C., Sept. 30, 2023 /PRNewswire-PRWeb/ -- The healthcare landscape in North Carolina reaches a pivotal milestone with the opening of the Center for Neuropsychiatry and Brain Stimulation (CNBS) in Cary. As the state's exclusive clinic offering a targeted approach to transcranial magnetic stimulation (TMS), including the novel MRI-guided TMS, CNBS stands at the forefront of medical innovation, providing renewed hope for individuals grappling with Major Depression, Anxiety, and other medication-resistant disorders.

Key Points: 
  • CARY, N.C., Sept. 30, 2023 /PRNewswire-PRWeb/ -- The healthcare landscape in North Carolina reaches a pivotal milestone with the opening of the Center for Neuropsychiatry and Brain Stimulation (CNBS) in Cary.
  • "CNBS signifies a new chapter in mental health treatment in North Carolina, a testament to remarkable strides in neuropsychiatry, offering innovative and personalized care on the path to recovery."
  • - Dr. Vaishnavi
    Transcranial Magnetic Stimulation (TMS) represents a groundbreaking leap in the treatment of persistent mental health conditions.
  • In addition to his medical expertise, Dr. Vaishnavi has penned "The Traumatized Brain", a comprehensive guide offering insights into brain injuries and their repercussions on mental health.